Absorption analysis specific drug

The difficulty with HLB as an index of physicochemical properties is that it is not a unique value, as the data of Zaslavsky et al. (1) on the haemolytic activity of three alkyl mercaptan polyoxyethylene derivatives clearly show in Table 1. Nevertheless data on promotion of the absorption of drugs by series of nonionic surfactants, when plotted as a function of HLB do show patterns of behaviour which can assist in pin-pointing the necessary lipophilicity required for optimal biological activity. It is evident however, that structural specificity plays a part in interactions of nonionic surfactants with biomembranes as shown in Table 1. It is reasonable to assume that membranes with different lipophilicities will"require" surfactants of different HLB to achieve penetration and fluidization one of the difficulties in discerning this optimal value of HLB resides in the problems of analysis of data in the literature. For example, Hirai et al. (8 ) examined the effect of a large series of alkyl polyoxyethylene ethers (C4,C0, Cj2 and C 2 series) on the absorption of insulin through the nasal mucosa of rats. Some results are shown in Table II. 

Specificity. For HPLC analysis, resolution of the drug substance from any potential excipient and system interference peaks should be demonstrated. For a UV-Vis analysis, the absorption of the placebo solution should not be significant. It is important to note that the dissolution test is not intended to be stability indicating and will not need to be able to separate degradation peaks from the analyte peak. 

Analytical absorption spectroscopy in the ultraviolet and visible regions of the elechomagnetic spectrum has been widely used in pharmaceutical and biomedical analysis for quantitative purposes and, with certain limitations, for the characterisation of drugs, impurities, metabolites, and related substances. By contrast, luminescence methods, and fluorescence spectroscopy in particular, have been less widely exploited, despite the undoubted advantages of greater specificity and sensitivity commonly observed for fluorescent species. However, the wider availability of spectrofluorimeters capable of presenting corrected excitation and emission spectra, coupled with the fact that reliable fluorogenic reactions now permit non-fluorescent species to be examined fluorimetrically, has led to a renaissance of interest in fluorimetric methods in biomedical analysis. 

Experimental limitations of the absorption models include poor solubility of the drug candidate in the aqueous buffers used, non-specific binding, and the lack of physiological relevance of the commonly used buffers. To guarantee high-throughput, the solvent systems used should also not add challenges to the analysis of the samples. 

As stated in the introduction, the submodels may differ in fixed or random effects. The task is to learn how to communicate our ideas about the submodels to NONMEM. Suppose that during a population pharmacokinetic (PK) analysis of an orally administered drug, a model is used where the absorption and elimination rates are first order. The model is parameterized in terms of elimination rate (K), apparent volume of distribution (Vd) and absorption rate (KA), such that both K and KA are allowed to vary between subjects. Specifically, the values of K and KA for the th subject (Kj and KAj) are specified as follows ... 

Structure identifiability problems may be avoided or significantly rednced by the use of the LSA approach. Specific kinetic processes snch as drug absorption and elimination may be analyzed in a more direct way by removing some structure complexity that otherwise may confound the analysis. 

Part V targets applications that are organized according to specific compound classes of analytes. The role of mass spectrometry in peptide and protein characterization and in proteomics is the subject of Chapter 18. Next, the topic of carbohydrate analysis by ESI and MALDI is tackled in Chapter 19. This is followed by an examination of ESI and MALDI applications to lipid analysis (Chapter 20). Finally, the important subject of drug discovery is addressed in Chapter 21, including in vitro ADME (absorption, distribution, metabolism and excretion) profiling and pharmacokinetic screening. 

---